Kirn D[Author] - Search Results

Year	Number of Results
1993	2
1994	1
1995	4
1996	6
1997	1
1998	4
1999	4
2000	13
2001	9
2002	10
2003	6
2004	8
2005	10
2006	4
2007	10
2008	15
2009	5
2010	9
2011	8
2012	5
2013	5
2014	2
2015	12
2016	5
2017	4
2018	6
2019	8
2020	3
2021	4
2022	5
2023	2
2024	2

1

Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies.

Salabarria SM, Corti M, Coleman KE, Wichman MB, Berthy JA, D'Souza P, Tifft CJ, Herzog RW, Elder ME, Shoemaker LR, Leon-Astudillo C, Tavakkoli F, Kirn DH, Schwartz JD, Byrne BJ. Salabarria SM, et al. Among authors: kirn dh. J Clin Invest. 2024 Jan 2;134(1):e173510. doi: 10.1172/JCI173510. J Clin Invest. 2024. PMID: 37988172 Free PMC article.

2

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer.

Kirn D. Kirn D. Oncogene. 2000 Dec 27;19(56):6660-9. doi: 10.1038/sj.onc.1204094. Oncogene. 2000. PMID: 11426652 Review.

3

Replication-selective adenoviruses as oncolytic agents.

Heise C, Kirn DH. Heise C, et al. Among authors: kirn dh. J Clin Invest. 2000 Apr;105(7):847-51. doi: 10.1172/JCI9762. J Clin Invest. 2000. PMID: 10749561 Free PMC article. Review. No abstract available.

4

Oncolytic biotherapy: a novel therapeutic plafform.

Hawkins LK, Lemoine NR, Kirn D. Hawkins LK, et al. Among authors: kirn d. Lancet Oncol. 2002 Jan;3(1):17-26. doi: 10.1016/s1470-2045(01)00618-0. Lancet Oncol. 2002. PMID: 11905600 Review.

5

Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.

Breitbach CJ, Parato K, Burke J, Hwang TH, Bell JC, Kirn DH. Breitbach CJ, et al. Among authors: kirn dh. Curr Opin Virol. 2015 Aug;13:49-54. doi: 10.1016/j.coviro.2015.03.016. Epub 2015 Apr 17. Curr Opin Virol. 2015. PMID: 25900822 Review.

6

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).

Breitbach CJ, Bell JC, Hwang TH, Kirn DH, Burke J. Breitbach CJ, et al. Among authors: kirn dh. Oncolytic Virother. 2015 Jan 28;4:25-31. doi: 10.2147/OV.S59640. eCollection 2015. Oncolytic Virother. 2015. PMID: 27512667 Free PMC article. Review.

7

Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease.

Yang HS, Yau WW, Carlyle BC, Trombetta BA, Zhang C, Shirzadi Z, Schultz AP, Pruzin JJ, Fitzpatrick CD, Kirn DR, Rabin JS, Buckley RF, Hohman TJ, Rentz DM, Tanzi RE, Johnson KA, Sperling RA, Arnold SE, Chhatwal JP. Yang HS, et al. Among authors: kirn dr. Brain. 2024 Feb 5:awae034. doi: 10.1093/brain/awae034. Online ahead of print. Brain. 2024. PMID: 38315899

8

Serum Predictors of Percent Lean Mass in Young Adults.

Lustgarten MS, Price LL, Phillips EM, Kirn DR, Mills J, Fielding RA. Lustgarten MS, et al. Among authors: kirn dr. J Strength Cond Res. 2016 Aug;30(8):2194-201. doi: 10.1519/JSC.0b013e31829eef24. J Strength Cond Res. 2016. PMID: 23774283

9

Vaccinia virus and oncolytic virotherapy of cancer.

Thorne SH, Hwang TH, Kirn DH. Thorne SH, et al. Among authors: kirn dh. Curr Opin Mol Ther. 2005 Aug;7(4):359-65. Curr Opin Mol Ther. 2005. PMID: 16121702 Review.

10

Recent advances in the development of oncolytic viruses as cancer therapeutics. Foreword.

Bell J, Kirn D. Bell J, et al. Among authors: kirn d. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):83-4. doi: 10.1016/j.cytogfr.2010.04.004. Epub 2010 May 4. Cytokine Growth Factor Rev. 2010. PMID: 20444639 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

175 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Results by year